Neogen Chemicals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/163fgay64dsbgvu97y5h4j56.pdf

Key Takeaways


Battery Chemicals: The Inflection Quarter

Dr. Harin Kanani: "Q4 is a quarter where we will have the non-China requirement start. So, we are expecting even a stronger Q4."

Base Business: The Silent Outperformer

Dr. Harin Kanani: "We have already got approvals in both, semiconductor materials as well as for the specialty polymers where also there is a strong volume demand."

The US Non-FEOC Opportunity

Dr. Harin Kanani: "By June next year, we would have access to the entire ecosystem of the U.S."

Margins: Volatility With a Long-Term Logic

Dr. Harin Kanani: "I know in the beginning this year and next year, the margins, there will be some volatility. But again you can focus on that or you can focus on the opportunity that we have for the next 10 years. As the entire ecosystem and business stabilises we request our investors to be a little bit more patient."

Balance Sheet & Capex: Funding the Buildout


The 10-Year Capacity Vision

Dr. Harin Kanani: "If within 10 years India reaches where China is today... Neogen also has a 30% kind of market share — based on just looking at the China model, no other logic. That also requires a 300 KT kind of electrolyte capacity and 380 KT salt capacity — approximately 10 times of what we have today."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 consolidated revenueClose to ₹1,350–1,400 croreFY27
FY27 base business revenue₹1,100 crore+ (upgraded from ₹950–1,050 crore)FY27
FY27 battery revenue₹250–300 crore (₹200 crore salt, ₹100 crore electrolyte); ₹300 crore still attemptedFY27
FY28 base business revenue₹1,200–1,300 crore (enhanced from ~₹1,150 crore)FY28
FY28 battery revenue₹1,000 crore+; ₹1,200–1,500 crore range depending on electrolyte developmentFY28
Organolithium capacity expansion300 MTPA to 600 MTPA; capex up to ₹45 croreCompletion by end of H1 FY28
Organolithium revenue contributionAdditional ₹50–75 crore in FY28; ₹150–200 crore at full run-rateFY28 / FY29
Pakhajan trial productionTrial production beginsDecember 2026
Pakhajan commercial quantitiesSignificant production quantitiesFebruary/March 2027
Dahej commercial productionCommence commercial productionWithin current financial year (FY27)
US ecosystem accessAccess to entire US electrolyte ecosystemBy June 2027
Neogen Ionics EBITDA positiveEBITDA positive on significant volumesQ4 FY27 / Q1 FY28
Neogen Ionics PBT positivePBT positiveSometime in next financial year (FY28)
Full utilisation financial target₹500 crore+ EBITDA, 20%+ ROCE on ~₹2,500–3,000 crore revenueFY29
Net debt FY28₹1,300–1,500 croreFY28
Inventory days~180 days by end FY27; 140–160 days FY28; 110–140 days FY29–30FY27–FY30
Salt capacity expansion decisionDecision on additional capacityBy Q4 FY27 / Q1 FY28
Next electrolyte capex decisionPlanning for next capacity increaseFY29 (to avoid shortfall by FY30)

Key Metrics

MetricQ2 FY27
Consolidated revenue₹296 crore, up 42% YoY
Consolidated EBITDA₹45 crore, up 51% YoY
Standalone EBITDA₹54 crore, up 54% YoY; margin 18.6%
Consolidated PAT₹8 crore, up 144% YoY
Standalone PAT₹21 crore, up 127% YoY
Battery chemicals revenue₹37 crore, vs ₹5 crore in Q2 FY26
Organic chemicals revenue₹238 crore, up 29% YoY
Inorganic chemicals revenue₹58 crore, up 140% YoY
Neogen Ionics revenue₹27 crore, vs ₹5 crore in Q2 FY26; equal to full-year FY26 sales
Consolidated net debt₹1,095 crore as of September 30, 2026
Standalone net debt₹378 crore as of September 30, 2026
Liquid investments (fixed deposits)₹465 crore as of September 30, 2026
FY27 consolidated revenue guidance₹1,350–1,400 crore, in line with or slightly better than previous guidance
FY27 battery chemicals guidance₹250–300 crore, previously ₹300 crore; ₹200 crore from salts, ₹100 crore from electrolyte
FY28 battery chemicals guidance₹1,000 crore+, range could be ₹1,200–1,500 crore depending on electrolyte
FY28 base business guidance₹1,200–1,300 crore, enhanced from earlier ~₹1,150 crore; includes Organolithium expansion
FY28 consolidated net debt expectation₹1,300–1,500 crore, depending on lithium prices
Organolithium capacity utilisation~25 tonnes per month (300 MTPA fully utilised)
Cumulative insurance recoveries to date₹164 crore, comprising ₹155 crore on-account payment and ₹9 crore salvage
Additional insurance claim accepted₹152 crore on October 29, 2026; total claims received and receivable now ₹316 crore
QIP fundraise₹600 crore, oversubscribed 6.5x
Credit ratingCRISIL A- stable (long-term outlook revised from negative), short-term reaffirmed at CRISIL A2+
Organolithium capacity expansion capexUp to ₹45 crore, doubling capacity from 300 MTPA to 600 MTPA; additional revenue potential ₹150–200 crore
Business transfer agreement (NML)₹245 crore on a going-concern basis, includes ₹77 crore infused by Morita via preference allotment
Inventory days target by end FY27~180 days
Battery business working capital cycle target~90 days